Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER-JM: once-monthly berobenatide in adults with obesity disease in Japan
jRCT2051260176Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Berobenatide with Placebo (2 arms). Primary endpoint: Percent change from baseline in body weight. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
berobenatide
03
Conditions
obesity
Beyond the preview
Go deeper on jRCT2051260176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260176.